Teva did everything in its power to block generic copies of lead drug Copaxone from hitting the market. But now that one is here--Novartis' Glatopa--the Israeli drugmaker's giant is faring better than industry watchers expected.
Sanofi's Aubagio may be stepping out of the shadow of its rivals. For the third quarter, Aubagio brought in €225 million ($247 million), an amount easily dwarfed by Gilenya's $696 million and Tecfidera's $937 million. But that was a major leap for Aubagio--81%--compared with slowing growth for the other two meds.
Roche's much-hyped multiple sclerosis treatment ocrelizumab kept up its momentum with the release of detailed late-stage data, burnishing hopes the injected drug is a blockbuster in the making.
Biogen, Sanofi and Novartis are all touting new data showing long-term benefits for their respective meds at this year's European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting--and with tough new competition on the way, they may need it.
Sanofi's multiple sclerosis pill Aubagio has been an also-ran behind established drugs like Teva's Copaxone and newer drugs like Biogen's Tecfidera. But the French drugmaker has not given up on it and today released data that might give it a new opening even as the MS market is shifting.
Roche's experimental therapy, ocrelizumab, recently posted positive Phase III data in patients with primary progressive multiple sclerosis, a less common form of the disease--affecting about 10% to 20% of sufferers--that right now remains untreated.
Roche is aiming to break into the multiple sclerosis field with ocrelizumab, an investigational therapy that marks the Swiss pharma giant's first foray into the disease area. And despite the big guns competing in the space, Roche may be able to corner a piece of the market for itself.
How do you keep a 22-year-old injectable multiple sclerosis therapy competitive in the face of threats from high-flying oral contenders? Bayer has an idea. The company recently won FDA approval for Betaconnect, an automatic injector it thinks can help keep its standby treatment, Betaseron, in the game.
Bayer is hoping that a new electronic autoinjector will slow the fall of lucrative multiple sclerosis drug Betaseron off of the dreaded patent expiry sales cliff.
An in-development drug from Roche performed well against a hard-to-treat form of multiple sclerosis in what the company says is a Phase III first that could shake up a $20 billion market.